12:00 AM
 | 
Jul 13, 2015
 |  BC Week In Review  |  Company News  |  Deals

Kode Biotech, Agalimmune deal

Kode granted Agalimmune exclusive rights to use Function-Spacer-Lipid (FSL) cell surface membrane technology in the field of intratumoral injection to treat cancer. Kode...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >